Skip to content
Screener

Krystal Biotech, Inc. KRYS Business Segments — Operating Income (Loss)

Similar metrics at other companies

Target logo
TGTReportable Segment — Operating Income (Loss)
$1.14B-22.9%
Ross Stores logo
ROSTReportable Segment — Operating Income (Loss)
$804.03M+32.6%
Williams-Sonoma logo
WSMReportable Segment — Operating Income (Loss)
$291.69M+0.3%
Samsara logo
IOTReportable Segment — Operating Income (Loss)
$7.2M+122%
ALX
ALXReportable Segment — Operating Income (Loss)
$24.43M-16.8%
The Buckle logo
BKEReportable Segment — Operating Income (Loss)
$59.45M+36.5%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)Three Months Ended / March 31, 2026March 31, 2025
Other research and development costs (1)7,7876,997
Total research and development15,33114,256
Selling, general and administrative41,01432,647
Income from operations$53,689$36,252
Other income
Interest and other income, net7,7537,345
Income before income taxes$61,442$43,597
Income tax expense(5,510)(7,864)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s business segments — operating income (loss)?
Krystal Biotech, Inc. (KRYS) reported business segments — operating income (loss) of $53.69M in Q1 2026.
How has Krystal Biotech, Inc.'s business segments — operating income (loss) changed year-over-year?
Krystal Biotech, Inc.'s business segments — operating income (loss) increased by 48.1% year-over-year, from $36.25M to $53.69M.
What is the long-term trend for Krystal Biotech, Inc.'s business segments — operating income (loss)?
Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — operating income (loss) has grown at a 3.5% compound annual growth rate (CAGR), from -$145.2M to $161.2M.
What does business segments — operating income (loss) mean?
Operating income represents the profit or loss generated by the segment's core business activities after deducting both cost of goods sold and operating expenses. It excludes non-operating items like interest, taxes, and one-time gains or charges.

Ask your AI about Krystal Biotech, Inc.'s business segments — operating income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude